Compagnie Chargeurs Invest (CRI) Q4 2021 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2021 earnings summary
5 Nov, 2026Executive summary
Record Q4 followed record Q3; FY2021 revenue was €736.6m, recurring operating profit €50.7m and attributable net profit €30.6m, each above 2019 levels.
Results were driven by CPF’s record business, recovery across textile activities and growth at CMS; all business lines were profitable.
Strong cash generation, controlled working capital and available financial resources supported accelerated growth and acquisition plans.
Financial highlights
FY2021 revenue was €736.6m, up 17.6% vs. 2019; EBITDA was €73.8m, up 23.0%, and recurring operating profit was €50.7m, up 22.5%.
Gross profit was €186.3m, or 25.3% of revenue; attributable net profit was €30.6m, up 103% vs. 2019, and EPS was €1.30.
Operating profit was €41.2m after €5.5m of acquisition-related intangible amortization and €4.0m of non-recurring expenses, mainly acquisitions and reorganizations.
Net cash from operating activities was €64.9m, up 155% vs. 2019; working capital contributed €21.9m at constant exchange rates.
Outlook and guidance
Leap Forward 2025 targets revenue of €1.5bn and recurring operating profit of €150m, combining embedded performance with acquisitions.
2022 performance drivers include CPF margin improvement from price increases, higher CFT-PCC volumes, CMS growth and a greater contribution from acquisitions.
Record order books at CPF, CFT-PCC and CMS supported the recovery outlook; CFT-PCC targeted a return to pre-COVID business levels during 2022.
Museum Studio had €140m of revenue signed for 2022–2025; its order-book-to-annual-revenue ratio was nearly 3x in early 2022.
Latest events from Compagnie Chargeurs Invest
- Revenue grew 8.7% like-for-like excluding healthcare as Luxury momentum strengthened.CRI
Q4 2022 - Q3 returned to growth, with Asia and high-end platforms leading the acceleration.CRI
Q3 2026 - Transformation to high-luxury focus, Novacel sale, and €14/share buyback drive strong outlook.CRI
Q2 2026 - Q1 2026 revenue fell, but strategic transformation accelerates with Novacel divestment and strong order books.CRI
Q1 2026 - Novacel sale and strategic refocus boost financial flexibility and target €1bn NAV by 2030.CRI
Q4 2025 - Stable H1 2025 revenue and NAV growth, strong Museum Studio gains, Novacel disposal under review.CRI
Q2 2025 - Revenue up 11.1% and recurring operating profit up 33.9%, with strong cash flow and reduced net debt.CRI
Q2 2024 - Strong growth, strategic transformation, and all resolutions passed amid market and regulatory risks.CRI
AGM 2025 - Museum Studio and Personal Goods drove 5.6% revenue growth in Q1 2025 amid global challenges.CRI
Q1 2025